Swedish Orphan Bio Spon (NASDAQ:SWTUY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Friday. The brokerage presently has a $18.00 price objective on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 14.50% from the company’s current price.

According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “

Swedish Orphan Bio Spon (SWTUY) opened at 15.72 on Friday. Swedish Orphan Bio Spon has a one year low of $10.25 and a one year high of $16.49. The company has a market cap of $4.23 billion and a PE ratio of 54.21. The firm’s 50-day moving average price is $15.72 and its 200-day moving average price is $15.03.

TRADEMARK VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/08/swedish-orphan-bio-spon-swtuy-upgraded-by-zacks-investment-research-to-buy.html.

Get a free copy of the Zacks research report on Swedish Orphan Bio Spon (SWTUY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Swedish Orphan Bio Spon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Bio Spon and related companies with MarketBeat.com's FREE daily email newsletter.